Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Perrigo has received final approval from the FDA for its abbreviated new drug application for clobetasol propionate foam, 0.05%.
Subscribe to our email newsletter
The product is a topical corticosteroid indicated for the treatment of moderate to severe dermatosis of the scalp. As the first filer, Perrigo will be eligible for 180 days of generic marketing exclusivity once it launches the product.
Joseph Papa, Perrigo’s chairman and CEO, said: “This approval reflects our on-going efforts to make quality healthcare more affordable for our customers and drive value for our shareholders.”